secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001193125-23-167929
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma grants 356,900 options to CEO and 153,000 to Exec Director at $0.23/share
--------------------------------------------------------------------------------

- CEO Dr. Jerel Banks granted nonqualified stock options for 356,900 shares at $0.23 per share.
- Executive Director Megan Boston granted nonqualified stock options for 153,000 shares at $0.23 per share.
- Options vest in three equal annual installments, subject to continued service through each vesting date.
- Unvested options fully accelerate upon a Change in Control as defined in the 2020 Equity Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523167929/0001193125-23-167929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523167929/d505671d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-167929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer